

# Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

## 1 Guideline

Gout: diagnosis and management

## 2 List of modelling questions

Review questions by scope area	<p><b>In people with gout (including people with gout and chronic kidney disease), which urate-lowering therapies (either alone or in combination with each other) are the most clinically and cost effective for first-line treatment?</b></p> <p><b>In gout that is inadequately controlled by first-line treatment, which urate-lowering therapies (either alone or in combination) are the most clinically and cost effective?</b></p> <p><b>If first-line treatment for gout is not tolerated, which urate-lowering therapies (either alone or in combination with each other) are the most clinically and cost effective?</b></p>
Population	Adults with gout who are eligible for first-line ULT
Interventions and comparators considered for inclusion	Febuxostat: Allopurinol Using a treat to target strategy.
Perspective	NHS and PSS
Outcomes	Costs
Type of analysis	Costing analysis
Modelling software	Excel
Issues to note	Due to a lack of robust clinical evidence the analysis was not able to capture long-term effects, quality of life impact or sequential use of different ULTs.
Review questions by scope area	<b>What is the optimum frequency of disease activity monitoring using serum urate level measurement in gout?</b>
Population	Adults with gout who have achieved target serum urate levels

## Economic Plan

Interventions and comparators considered for inclusion	Annual monitoring: No monitoring
Perspective	NHS and PSS
Outcomes	Number of flares needed to be avoided per person per year for the cost of annual monitoring to break even
Type of analysis	Costing analysis
Modelling software	Excel
Issues to note	None